Cantor Fitzgerald Comments on Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Disc Medicine in a report issued on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($4.69) for the year, down from their previous forecast of ($4.59). Cantor Fitzgerald currently has a “Overweight” rating and a $132.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

A number of other analysts have also recently weighed in on IRON. TD Cowen began coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. Stifel Nicolaus lifted their target price on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Scotiabank upped their price objective on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, March 3rd. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $93.80.

Disc Medicine Stock Down 0.1%

Shares of NASDAQ:IRON opened at $44.24 on Monday. Disc Medicine has a fifty-two week low of $30.65 and a fifty-two week high of $68.73. The firm’s 50 day moving average price is $46.93 and its 200 day moving average price is $54.98. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -11.12 and a beta of 0.77.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC lifted its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after purchasing an additional 503 shares in the last quarter. Amalgamated Bank grew its stake in shares of Disc Medicine by 38.6% during the first quarter. Amalgamated Bank now owns 787 shares of the company’s stock valued at $39,000 after acquiring an additional 219 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Disc Medicine during the 4th quarter worth approximately $40,000. Tower Research Capital LLC TRC increased its stake in shares of Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after buying an additional 266 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Disc Medicine during the fourth quarter worth about $235,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Disc Medicine news, Director Mona Ashiya sold 5,738 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $54.11, for a total transaction of $310,483.18. Following the transaction, the director now owns 186,541 shares of the company’s stock, valued at $10,093,733.51. This represents a 2.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider William Jacob Savage sold 2,100 shares of the stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $50.17, for a total value of $105,357.00. Following the transaction, the insider now owns 66,398 shares in the company, valued at $3,331,187.66. This trade represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 356,290 shares of company stock worth $19,336,901. Insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.